SMN2 and proximal spinal muscular atrophy: Currently, the Italian health regulatory agency allows treatment with gene therapy for children with SMA up to 13.5 kg and presymptomatic babies with ≤3 SMN2 copies, whereas nusinersen and risdiplam can be administered at all ages to presymptomatic SMA patients with one to four SMN2 copies.